Oncoinsight
1 known investors
OncoInsight develops off-the-shelf natural killer (NK) cell therapy product candidates aimed at treating cancer patients. The company operates in the biotech and cell therapy space.
Also known as OncoInsight · Oncoinsight Co. Ltd. · 온코인사이트
Investors · 1
Company profile
researched Aug 2026Oncoinsight Co. Ltd. (온코인사이트) is a South Korean cell therapy company headquartered in Seoul that discovers and develops off-the-shelf natural killer (NK) cell therapy product candidates. Its stated mission is to develop novel allogeneic NK cell therapies for cancer patients, and its vision is to deliver accessible cell therapies. The company's programs center on allogeneic NK cells engineered against solid tumors, on CAR hematopoietic stem cell (HSC)-derived NK cells for B cell-driven autoimmune diseases such as lupus, and on humanized mouse models used for human-specific immunological studies.
A drug pipeline database profile lists Oncoinsight as founded in 2017 and based in Seoul, with 12 associated drugs spanning CAR-NK, cell therapy, hematopoietic stem cell therapy, induced pluripotent stem cell (iPSC) and CAR-M drug types, and disease domains led by neoplasms (11 entries) plus immune system, endocrine/metabolic and infectious disease entries. Named candidates include OI-204 (solid tumor, preclinical), OI-202 (solid tumor, preclinical) and OI-112 (triple negative breast cancer, preclinical), the last of which lists Catalent, Inc. among active organizations while Oncoinsight is the originator.
The company's site presents sections for science, pipeline and open innovation, and lists an executive team of Deukchae Na, Ph.D. (Chief Executive Officer), Miyeon Lee, MOT (Chief Operating Officer) and Kyoungwoon Kim, Ph.D. (Director), together with a scientific advisory board that includes Junwoo Lee, M.D.
Latest developments
As of a May 2025 database update, Oncoinsight is listed as originator of preclinical candidates OI-204 and OI-202 for solid tumors and OI-112 for triple negative breast cancer, with Catalent, Inc. listed among the active organizations for OI-112.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
A preclinical-stage Korean developer of allogeneic CAR-NK cell therapies; its listed candidates OI-204, OI-202 and OI-112 are all at preclinical phase as of May 2025.
The company positions allogeneic NK cell products as capable of being manufactured as universal, off-the-shelf therapies with a safety profile it describes as better than CAR-T cell therapy, and extends the modality beyond oncology into B cell-driven autoimmune disease via CAR HSC-derived NK cells.
Technology
The company works on allogeneic natural killer cell platforms. It states that NK cells can be xenografted and have the potential to be produced as off-the-shelf, universal CAR-NK products, which it describes as safer than CAR-T cell therapy. A second approach uses CAR HSC-derived NK cells intended for B cell-driven autoimmune indications including lupus. The company also uses humanized mice, which support development of multiple functional components of the human immune system, as tools for human-specific studies. Pipeline database tagging lists CAR-NK, cell therapy, hematopoietic stem cell therapy, iPSC and CAR-M among its drug types.
Go-to-market
Cancer patients, including those with solid tumors and triple negative breast cancer, and patients with B cell-driven autoimmune diseases such as lupus.
Geography
Headquartered in Seoul, South Korea, at the 5th and 6th floors of the R&D Block, Omnibus Park, 222 Banpo-daero, Seocho-gu (06591).
History
A pipeline database profile records the company as established in 2017 in Seoul, South Korea.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
▸Research sources · 6
primary sources listed
- Oncoinsightoncoinsight.co.kr · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Oncoinsight do?
- Seoul-based biotech developing allogeneic, off-the-shelf CAR-NK cell therapies for solid tumors and autoimmune disease.
- Who are Oncoinsight's investors?
- Oncoinsight's investors include Kiwoom Investment.